<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00456027</url>
  </required_header>
  <id_info>
    <org_study_id>D/P2/04/2</org_study_id>
    <secondary_id>EUDRACT 2004-001998-25</secondary_id>
    <nct_id>NCT00456027</nct_id>
  </id_info>
  <brief_title>Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult)</brief_title>
  <official_title>A Placebo-Controlled Study to Investigate the Impact of Diamyd® on the Diabetes Status of Patients With LADA (Latent Autoimmune Diabetes in Adult)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diamyd Therapeutics AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diamyd Therapeutics AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to investigate the safety of 20ug Diamyd® (rhGAD65 formulated in
      Alhydrogel®), administered subcutaneously four weeks apart in patients with Latent Autoimmune
      Diabetes in Adult (LADA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The development over time of safety variables, i.e. injection site discomfort, vital signs, laboratory values and AEs/SAEs as well as development of diabetes status, i.e. HbA1c, C-peptide, blood glucose and insulin requirement.</measure>
    <time_frame>30 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">160</enrollment>
  <condition>Latent Autoimmune Diabetes in Adult (LADA)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhGAD65 formulated in Alhydrogel® (Diamyd®)</intervention_name>
    <description>20 micrograms of rhGAD65 formulated in Alhydrogel® administered subcutaneously twice 4 weeks apart</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male and female patients between 30-70 years of age diagnosed with type 2 diabetes
             within 5 years

          -  Presence of GAD65 antibodies

          -  Detectable C-peptide level

          -  Patients requiring treatment with diet and/or oral hypoglycaemic agents (OHA)

          -  Written informed Consent

        Key Exclusion Criteria:

          -  Treatment with insulin

          -  Intolerance to OHA

          -  Secondary diabetes mellitus

          -  History of certain diseases or conditions (e.g. anaemia, epilepsy, head trauma,
             neurological disease, alcohol or drug abuse, HIV, hepatitis)

          -  Treatment with any vaccine within one month prior to first Diamyd® dose or planned
             treatment with vaccine up to 2 months after the second Diamyd® dose

          -  Participation in other clinical trials with a new chemical entity within the previous
             3 months

          -  Pregnancy (or planned pregnancy within one year after 2nd administration)

          -  Presence of associated serious disease or condition which in the opinion of the
             investigator makes the patient non-eligible for the study

          -  Significant illness other than diabetes within 2 weeks prior to first dosing

          -  Unwillingness to comply with the provisions of the protocol

          -  Clinically significant history of acute reaction to drugs in the past

          -  Treatment with immunosuppressants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl-David Agardh, MD, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital MAS, Malmö, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alingsås Hospital</name>
      <address>
        <city>Alingsås</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Falu Hospital</name>
      <address>
        <city>Falun</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capio Lundby Hospital</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsingborg Hospital</name>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Härnösand Hospital</name>
      <address>
        <city>Härnösand</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karlstad Central Hospital</name>
      <address>
        <city>Karlstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Hospital, Kristianstad</name>
      <address>
        <city>Kristianstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunderby Hospital</name>
      <address>
        <city>Luleå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital MAS</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrinnevi Hospital</name>
      <address>
        <city>Norrköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skellefteå Hospital</name>
      <address>
        <city>Skellefteå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S:t Göran Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stockholm South General Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norrlands University Hospital</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Växjö Central Hospital</name>
      <address>
        <city>Växjö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odensala Health Clinic</name>
      <address>
        <city>Östersund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2007</study_first_submitted>
  <study_first_submitted_qc>April 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2007</study_first_posted>
  <last_update_submitted>June 9, 2011</last_update_submitted>
  <last_update_submitted_qc>June 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Managing Director</name_title>
    <organization>Diamyd Therapeutics AB</organization>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>LADA</keyword>
  <keyword>Latent Autoimmune Diabetes in Adult</keyword>
  <keyword>Autoimmunity</keyword>
  <keyword>HbA1c</keyword>
  <keyword>C-peptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Latent Autoimmune Diabetes in Adults</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

